While many investors focus on the popular, large publicly traded stocks, there is massive potential in trading the lesser-known stocks available on the OTC markets.
OTC stocks that have recently dropped in price may present a unique opportunity for investors to profit. Investing in these stocks allows you to get in at a lower price point, which leads to larger potential gains in the long run.
Let's take a look at four stocks on the OTC markets worth considering that have dropped in price recently.
One stock that has been selling off but may offer investors willing to step in an interesting opportunity is Todos Medical Ltd. (OTC: TOMDF). Todos Medical is a provider of in vitro diagnostics with a focus on the creation of cutting-edge blood tests for the early diagnosis of cancer and neurodegenerative diseases like Alzheimer's, as well as the distribution of comprehensive COVID-19 screening solutions.
The company has engineered the early cancer detection technology, Todos Biochemical Infrared Analyses, or TBIA. Todos' two internally developed cancer-screening tests, TMB-1 and TMB-2, have been CE-marked in Europe.
Last year, Todos Medical acquired Provista Diagnostics, Inc., a medical diagnostics business based in the United States. Through this acquisition, TOMDF gained access to Provista's CLIA/CAP-certified lab, which performs long COVID panel analyzes in addition to PCR COVID testing. TOMDF also took ownership of Provista's proprietary commercial-stage Videssa breast cancer blood test.
TOMDF also offers Tollovid, a 3CL protease inhibitor dietary supplement to support healthy immune function against circulating coronaviruses, and Tollovir, an antiviral treatment for Covid-19 that is in Phase 2 clinical trial.
The company is building a solid portfolio of technologies and intellectual properties surrounding cancer detection of various kinds, COVID-19 detection and treatment, and Alzeimer's disease detection. Investors looking for an interesting opportunity at a low barrier of entry should add TOMDF to their watchlist.
Regen BioPharma, Inc. (PINK: RGBP) is a biotechnology company focused on the immunology and immunotherapy space. RGBP is developing novel technologies through preclinical research and Phase I and II clinical trials. They are currently concentrating on mRNA and small molecule therapies for cancer and autoimmune disorders.
The business announced on February 7 that it would be giving a presentation at the Emerging Growth Conference on February 8. The Emerging Growth Conference is an interactive online event that will allow existing shareholders and the investment community to interact in real time with Dr. David Koos, CEO of Regen BioPharma.
“We plan to use this time to update our stakeholders on our corporate strategic plans, drug pipeline, drug development strategy, and answer shareholder questions," says Dr. David Koos. "We also plan to address Regen's forthcoming 1 for 1500 reverse stock split affecting all series of stock. We feel that effecting this change is integral to furthering the Company's objectives of seeking uplistings for our Common and series A Preferred Stock as well as making our stock more attractive to institutional investors." The reverse stock split will be effective March 6, 2023.
PHI Group, Inc. (OTC: PHIL), also known as Philux Global Group, focuses primarily on Philux Global Funds, a collection of Luxembourg bank funds structured as a "Reserved Alternative Investment Fund." The company is also involved in building the Asia Diamond Exchange (“ADE”) in Vietnam. PHIL also engages in mergers and acquisitions as well as invests in selective industries and special situations that boost shareholder value.
The company expects to file the 10-Q report for the quarter ended September 30, 2022, in the coming days to become current with the US Securities and Exchange Commission as a fully-reporting company and also file the 10-Q for the quarter ended December 31, 2022, quickly thereafter.
On February 7, PHIL announced that the Vietnamese construction and infrastructure development company, Thanh Nam Long Co., Ltd., has signed an agreement with Philux Global to join the “PHILUX Infrastructure Fund.” This Luxembourg-based infrastructure fund focuses on the development and implementation of select infrastructure projects in Vietnam and other geographical areas.
Henry Fahman, Chairman and CEO of Philux Global Group, stated: “We are delighted to partner with Thanh Nam Long to advance the PHILUX Infrastructure Fund for Vietnam and are confident that we will be well positioned to serve Vietnam’s infrastructure needs as well as create significant benefits for both companies, our shareholders and all other stakeholders involved.”
AiAdvertising, Inc. (OTC: AIAD) is a next-generation AdTech company that is harnessing the power of artificial intelligence (AI) and machine learning (ML) to build software for today's marketing leaders.
Last week, AiAdvertising announced that they will use the automated ChatGPT from OpenAI as a tool for enhancing personas and persona-driven campaigns for their clients. The ChatGPT platform has been making headlines for attracting major investments from tech giants, and AiAdvertising has already begun incorporating the chatbot program into the development of its advertising campaigns to help its customers generate more revenue from the platforms they use.
Jerry Hug, CEO of AiAdvertising, said, “We continue to explore and test many types of AI technology with the goal of integrating the best of breed into our platform. We plan to infuse the ChatGPT technology into our platform in various ways, from gaining market intelligence to improving persona narratives to generating persona-driven ad content, email campaigns, and landing page copy.”
Disclaimers: This article contains sponsored content. The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor with regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, assumptions, objectives, goals, and assumptions about future events or performance are not statements of historical fact and may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties that could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements, indicating certain actions & quotes; may, could or might occur Understand there is no guarantee past performance is indicative of future results. Investing in micro-cap or growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor's investment may be lost or due to the speculative nature of the companies profiled. CaptalGainsReport 'CGR' (owned by RazorPitch Inc.) is responsible for the production and distribution of this content. CGR is not operated by a licensed broker, a dealer, or a registered investment advisor. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. CGR authors, contributors, or its agents, may be compensated for preparing research, video graphics, and editorial content. CGR has been compensated by Todos Medical to produce and syndicate content for TOMDF. As part of that content, readers, subscribers, and webs are expected to read the full disclaimers and financial disclosure statement that can be found on our website.
CapitalGainsReport is a financial website and newsletter for investors seeking nanocap and microcap opportunities. Please join our free newsletter at CapitalGainsReport.com
View source version on newsdirect.com: https://newsdirect.com/news/capitalgainsreport-todays-otc-bounce-watchlist-tomdf-phil-rgbp-aiad-339851260